Transplantation of the pancreas in Turkey: surgical purpose and clinical mechanism
Transplantation of the pancreas is a major surgical procedure in which a healthy donor pancreas—containing functional beta cells within the islets of Langerhans—is implanted into a recipient with severe pancreatic endocrine failure. In the vast majority of cases, the operation is performed for individuals with Type 1 diabetes who suffer from life-threatening metabolic instability or end-stage diabetic kidney disease. Unlike standard metabolic surgeries or hormone injections, a successful vascularised graft establishes immediate, physiological insulin and glucagon secretion in response to fluctuating blood glucose levels, effectively halting extreme glycaemic swings.
Pancreas grafting is technically demanding because the organ serves both endocrine (hormone production) and exocrine (digestive enzyme production) functions. During surgery, the donor organ is placed heterotopically in the lower abdomen, typically within the right or left iliac fossa, leaving the recipient's native pancreas intact to continue producing digestive enzymes. Turkish tertiary hospitals perform these complex abdominal procedures within multidisciplinary organ transplant units. For a broader overview of abdominal and digestive organ procedures, see our guide to gastroenterology treatments in Turkey.
Types of pancreas transplantation: SPK, PAK, and PTA
Pancreas transplantation is categorised into three distinct surgical approaches depending on the patient's renal status. Simultaneous pancreas-kidney (SPK) transplantation represents approximately 75 to 80 per cent of all cases worldwide. It is indicated for patients with Type 1 diabetes who have reached end-stage renal disease or severe diabetic nephropathy requiring dialysis. Receiving both organs from the same deceased donor provides dual organ replacement in a single operation, protecting the new kidney graft from recurring diabetic nephropathy.
Pancreas after kidney (PAK) transplantation is performed for patients who have previously received a successful kidney graft, frequently from a living related donor, and subsequently undergo a secondary pancreas transplant once renal function is stable. This staged pathway minimises time spent on dialysis while allowing optimal scheduling of the living-donor renal procedure.
Pancreas transplant alone (PTA) is reserved for individuals with Type 1 diabetes who maintain preserved renal function but suffer from severe, brittle diabetes characterised by frequent, unheralded hypoglycaemia (hypoglycaemic unawareness) that fails to respond to intensive medical therapy. While PTA restores glycaemic control, the decision to proceed requires careful clinical balancing, as the patient must accept the lifelong risks of immunosuppression to treat metabolic lability.
Does transplantation of the pancreas work? What clinical evidence shows
Clinical registry data from the International Pancreas Transplant Registry and international transplant societies demonstrate that transplantation of the pancreas reliably restores normoglycaemia and eliminates the need for exogenous insulin injections in the majority of recipients. Following successful simultaneous pancreas-kidney transplantation, one-year pancreas graft survival exceeds 85 to 90 per cent in high-volume centres, with patient survival rates surpassing 95 per cent. At five years, functioning graft rates remain approximately 70 to 80 per cent.
The evidence confirms significant systemic benefits beyond blood sugar normalisation. Restoring continuous, endogenous insulin and C-peptide secretion halts or slows the progression of secondary diabetic complications, including autonomic neuropathy, diabetic retinopathy, and macrovascular disease. In SPK recipients, long-term survival is demonstrably higher than for diabetic patients remaining on dialysis. However, clinical evidence is equally clear about the limitations: the surgery does not reverse advanced, fixed end-organ damage such as blindness or severe peripheral vascular necrosis, and graft function can deteriorate over time through chronic rejection or drug-induced toxicity. A reputable surgical team will never frame the procedure as a simple cure, but rather as an exchange of severe, unstable diabetes for manageable, medically monitored immunosuppression.
Transplantation of the pancreas cost: Turkey, the UK, US, and Germany compared
The cost of pancreas transplantation varies considerably across international healthcare systems. Solid organ transplantation represents one of the most resource-intensive medical interventions, requiring multidisciplinary surgical teams, extensive pre-transplant immunogenetic testing, extended intensive care monitoring, and specialist pharmacology. The table below presents approximate cost ranges across major destinations. These figures reflect estimated hospital charges for evaluation, surgical procedure, and acute inpatient recovery, rather than binding individual quotations.
| Country | Approximate cost range |
|---|---|
| Turkey | €45,000 – €95,000 |
| United Kingdom | €75,000 – €160,000 |
| United States | €180,000 – €380,000 |
| Germany | €85,000 – €190,000 |
Several clinical and administrative variables account for transplantation of the pancreas cost differences. A combined SPK procedure involves greater operating theatre time, two organ procurements, and dual surgical teams compared with a solitary transplant. Other cost drivers include the length of stay in the intensive care unit, requirements for blood products or dialysis, induction antibody therapies, and the management of acute post-operative events. In Turkey, treatment packages for international patients typically include pre-transplant crossmatching and tissue typing, surgeon and anaesthetic fees, hospital stay, initial maintenance immunosuppressants, nursing care, and local transfer services. Extended post-discharge outpatient monitoring and long-term medications are usually budgeted separately.
Pancreas transplant vs islet cell transplantation vs automated insulin pumps
Patients exploring therapeutic options for brittle diabetes often compare whole-organ vascularised pancreas grafting with less invasive alternatives. Islet cell transplantation involves isolating insulin-producing islets from a donor pancreas and infusing them percutaneously into the recipient's portal vein under radiological guidance. While islet transplantation avoids major abdominal surgery, it often requires tissue from multiple donors to achieve insulin independence, and graft function typically wanes more rapidly over five years than that of a vascularised whole-organ graft.
Conversely, modern automated insulin delivery systems—often termed hybrid closed-loop or bionic pancreas devices—combine continuous glucose monitors with algorithmic subcutaneous insulin pumps. These non-surgical technologies dramatically reduce hypoglycaemia without requiring surgical intervention or immunosuppressive medications, though they do not restore natural endogenous C-peptide or physiological pancreatic counter-regulation. Organ transplant units frequently coordinate with hepatobiliary specialists; see our guide to liver transplantation for comparison of complex vascular organ grafting and immunology.
| Method | Best suited to | Typical limits |
|---|---|---|
| Simultaneous Pancreas-Kidney (SPK) | Type 1 diabetes with end-stage renal failure or dialysis dependency | Major dual-organ open surgery; lifelong immunosuppression required |
| Pancreas Transplant Alone (PTA) | Severe brittle diabetes with life-threatening hypoglycaemic unawareness | Surgical morbidity; potential nephrotoxicity from maintenance immunosuppressants |
| Islet Cell Transplantation | Patients at prohibitive surgical risk needing cellular glycaemic stabilisation | Frequently requires multiple donor infusions; lower long-term insulin independence |
| Automated Closed-Loop Pump | Patients seeking tight glucose control without surgical intervention | External hardware dependence; does not produce endogenous biological insulin |
Who is an appropriate candidate for pancreas transplant surgery?
Determining candidate suitability involves rigorous, multi-system screening to ensure the potential survival and quality-of-life benefits outweigh the considerable surgical and pharmacological risks. The primary indication is medically refractory Type 1 diabetes with frequent severe hypoglycaemic unawareness, recurrent diabetic ketoacidosis, or concurrent end-stage diabetic nephropathy. Selected patients with insulin-dependent secondary or pancreatogenic diabetes (such as following total pancreatectomy) may also be evaluated on an individual basis.
Conversely, several medical conditions represent significant contraindications. Candidates are generally excluded if they present with active or untreated systemic malignancy, severe uncorrectable coronary artery disease, active substance dependency, uncontrolled systemic infections, severe pulmonary hypertension, or advanced peripheral vascular calcification that precludes safe vascular anastomosis. Patients with high surgical frailty or documented non-adherence to complex medical regimens are likewise unsuitable, as strict adherence to daily immunosuppression is essential to avoid catastrophic graft rejection.
The surgical procedure step by step: vascular and enteric reconstruction
Pancreas transplant surgery is performed under general anaesthesia and typically lasts between three and six hours for a solitary procedure, or up to eight hours when combined with a renal transplant. The surgical team makes a midline or lower abdominal incision. The donor pancreas is prepared on a sterile back table, where the splenic artery and superior mesenteric artery are commonly reconstructed using a donor iliac arterial Y-graft to create a single arterial inflow conduit.
The graft is then placed heterotopically in the recipient's right or left iliac fossa. Vascular reconstruction begins with anastomosing the donor portal vein to the recipient's external iliac vein or superior mesenteric vein, providing venous drainage. Next, the arterial Y-graft is connected to the recipient's common or external iliac artery to re-establish blood flow. Upon unclamping, the graft reperfuses, taking on a healthy pink appearance and beginning immediate insulin release.
Managing the exocrine secretions (pancreatic digestive enzymes) is the final critical step. In modern transplantation, enteric drainage is the preferred standard: the donor duodenal segment attached to the pancreas is anastomosed directly to the recipient's small intestine (jejunum or ileum), allowing digestive enzymes to drain naturally into the bowel. Bladder drainage, an older technique in which exocrine secretions were routed into the urinary bladder, is now rarely used due to frequent metabolic acidosis and urological complications. Once haemostasis is confirmed and surgical drains are positioned, the abdominal layers are closed.
Recovery milestones and trip planning after pancreas transplantation
Transplantation of the pancreas recovery is extensive and requires phased clinical monitoring. Immediately following the operation, patients are transferred to an intensive care unit for two to four days of continuous haemodynamic monitoring, blood glucose tracking, and doppler ultrasound evaluation of graft vascular patency. Once stabilised, patients move to a dedicated surgical ward for an additional seven to fourteen days to manage pain, advance oral nutrition, and titrate immunosuppressive drug levels.
For international patients travelling to Turkey, the total stay typically spans four to six weeks. This extended period ensures complete wound healing, removal of surgical drains, and frequent outpatient laboratory checks for blood counts, serum creatinine, amylase, lipase, and immunosuppressant trough levels. To understand how clinical evaluations and diagnostic files are managed prior to international travel, read how it works.
Physical recovery proceeds gradually over three to six months. Gentle walking begins during the first hospital week, but heavy lifting and strenuous physical activities are restricted for at least eight to twelve weeks to prevent incisional hernias. Desk-based professional activities may resume after two to three months, provided infection risks are carefully managed. Regular blood monitoring remains mandatory throughout the patient's life to detect subtle signs of organ rejection or drug toxicity early.
Metabolic outcomes and realistic before-and-after expectations
Unlike cosmetic procedures evaluated through aesthetic photographs, pancreas transplant results are measured through objective biochemical parameters and metabolic stability. Before surgery, patients struggle with erratic blood sugar levels, severe hypoglycaemic episodes, constant fingerstick testing, and multiple daily insulin injections or pump management. After successful surgery, functioning donor islets begin producing insulin immediately upon reperfusion, allowing the discontinuation of exogenous insulin therapy often within hours or days.
Long-term post-operative testing typically demonstrates normal fasting glucose levels, normalisation of glycated haemoglobin (HbA1c below 6.0%), and measurable levels of circulating C-peptide. Patients report dramatic improvements in energy levels, dietary freedom, and relief from the persistent fear of nocturnal hypoglycaemia. However, realistic expectations are paramount: recipients trade the daily burdens of diabetes management for the rigorous schedule of immunosuppressive medications, frequent blood tests, and increased vulnerability to infections. Furthermore, surgical scars across the lower abdomen remain visible and permanent.
Surgical risks, graft failure, and immunosuppression complications
Pancreas transplant risks carry substantial surgical and medical hazards that require candid pre-operative discussion. Early surgical complications occur in up to 25 per cent of recipients. The most critical early vascular hazard is graft thrombosis (blood clot formation in the low-flow pancreatic splenic or portal vessels), which occurs in roughly 5 to 10 per cent of cases and frequently necessitates emergent graft removal. Other surgical risks include acute graft pancreatitis, intra-abdominal bleeding, anastomotic leaks at the enteric connection, and deep wound infections.
Secondary risks relate to long-term immunosuppression and immune rejection. According to clinical guidance from the National Health Service (NHS) and the American Society of Transplantation (AST), acute cellular or antibody-mediated rejection can occur at any stage, requiring prompt biopsy and intensified antirejection therapy. Chronic maintenance medications (such as tacrolimus, mycophenolate, and corticosteroids) increase susceptibility to opportunistic bacterial, viral (such as cytomegalovirus), and fungal infections, while elevating long-term risks of nephrotoxicity, hypertension, hyperlipidaemia, and secondary malignancies including post-transplant lymphoproliferative disorder (PTLD). Complex abdominal organ surgeries require institutional accreditation comparable to major hepatic programmes; learn more about liver transplantation protocols and hepatobiliary care.
Choosing a certified transplant centre and questions to ask
Selecting an appropriate surgical facility for complex organ transplantation requires rigorous due diligence. Patients must verify that the hospital holds national licensing from the Turkish Ministry of Health for solid organ transplantation and carries international quality accreditation, such as Joint Commission International (JCI). The centre should maintain dedicated organ transplant surgical suites, 24-hour interventional radiology, fully equipped intensive care facilities, and specialised histopathology services capable of performing rapid graft biopsies.
Red flags include any clinic that trivialises the complexity of transplant surgery, guarantees permanent insulin independence, provides vague cost estimates without detailed inclusions, or lacks an established multi-organ transplant team. To review your medical files with a clinical specialist, request a comprehensive evaluation through our free quote service. You can also explore related surgical specialities through our main portal for gastroenterology treatments in Turkey.
When consulting with the transplant coordinator and surgical team, consider asking the following questions:
- How many pancreas transplant procedures does your surgical team perform each year?
- What are your centre's specific one-year and five-year patient and graft survival rates?
- What vascular and enteric drainage techniques does the surgical team routinely utilise?
- What protocol is in place for emergency graft thrombosis or acute rejection episodes?
- How will my maintenance immunosuppression levels be monitored once I return to my home country?
- What exact medical services, hospital days, and laboratory tests are included in the written quote?
Hospitals with Gastroenterology in Turkey
Frequently asked questions
Transplantation of the pancreas is a complex surgical procedure that implants a healthy donor pancreas into a person with severe Type 1 diabetes. The transplanted organ restores natural insulin and glucagon production, eliminating extreme blood glucose swings and dependency on exogenous insulin injections.
Yes, clinical registry data show that over 85 to 90 per cent of pancreas grafts function successfully at one year, restoring normal blood sugar levels and eliminating hypoglycaemia. However, patients must take daily immunosuppressive medications indefinitely to prevent organ rejection, which carries its own long-term health risks.
Approximate costs in Turkey typically range from €45,000 to €95,000, depending on whether the surgery is performed alone or combined with a kidney transplant. In the UK, private or non-NHS care can exceed €75,000 to €160,000, while US hospital charges frequently surpass €180,000.
Unlike cosmetic procedures, outcomes are metabolic rather than visual. Before surgery, patients face frequent fingerstick tests, severe hypoglycaemic crises, and insulin injections. Afterwards, successful recipients achieve normal HbA1c levels without insulin, though they have permanent lower abdominal surgical scars and follow a strict medication routine.
Whole-organ pancreas transplantation involves major vascular surgery but provides higher and more durable rates of complete insulin independence. Islet cell transplantation is a minimally invasive infusion into the liver portal vein, but often requires multiple donors and shows lower rates of sustained long-term insulin freedom.
Inpatient hospital recovery typically lasts two to three weeks, including several days in intensive care. Most patients require three to six months for full physical recovery before returning to routine work, and strenuous exercise or heavy lifting is restricted for at least eight to twelve weeks.
Because the operation involves a major abdominal incision, moderate to severe post-operative pain is expected during the first few days. Pain is managed through intravenous analgesia and epidural or patient-controlled pumps in the hospital, transitioning to oral pain medications as the wound heals.
On average, a transplanted pancreas functions for ten to fifteen years or more, with many surviving longer under diligent immunosuppressive monitoring. Graft longevity depends on avoiding acute rejection episodes, managing cardiovascular health, adhering to prescribed medications, and preventing chronic graft fibrosis.
Major surgical risks include early graft thrombosis, which affects 5 to 10 per cent of patients and often requires graft removal, as well as graft pancreatitis, bleeding, anastomotic leaks, and intra-abdominal infections. Long-term risks stem from immunosuppression, including opportunistic infections and renal toxicity.
International patients typically need to stay in Turkey for four to six weeks. This timeframe covers pre-transplant crossmatching and immunological workups, the hospital admission of two to three weeks, and subsequent outpatient surveillance to stabilise immunosuppressant drug levels before returning home.